Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Operating Leases (2021 - 2025)

Historic Operating Leases for Sutro Biopharma (STRO) over the last 5 years, with Q3 2025 value amounting to $9.7 million.

  • Sutro Biopharma's Operating Leases fell 4507.11% to $9.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year decrease of 4507.11%. This contributed to the annual value of $15.7 million for FY2024, which is 3230.54% down from last year.
  • Per Sutro Biopharma's latest filing, its Operating Leases stood at $9.7 million for Q3 2025, which was down 4507.11% from $11.5 million recorded in Q2 2025.
  • Sutro Biopharma's Operating Leases' 5-year high stood at $32.1 million during Q3 2021, with a 5-year trough of $9.7 million in Q3 2025.
  • In the last 5 years, Sutro Biopharma's Operating Leases had a median value of $24.9 million in 2023 and averaged $23.5 million.
  • As far as peak fluctuations go, Sutro Biopharma's Operating Leases plummeted by 322.7% in 2022, and later tumbled by 4507.11% in 2025.
  • Over the past 5 years, Sutro Biopharma's Operating Leases (Quarter) stood at $31.2 million in 2021, then fell by 5.28% to $29.6 million in 2022, then fell by 21.71% to $23.2 million in 2023, then plummeted by 32.31% to $15.7 million in 2024, then plummeted by 38.11% to $9.7 million in 2025.
  • Its Operating Leases stands at $9.7 million for Q3 2025, versus $11.5 million for Q2 2025 and $13.6 million for Q1 2025.